复宏汉霖科学家团队合作撰写的《Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®》一文在抗体领域权威杂志mAbs上成功发表，该研究证实了中国首个获批的生物类似药复宏汉霖汉利康®（HLX01）与原研药美罗华®在产品质量上的高度相似性，与HLX01在临床研究中展现的疗效和安全性保持了高度一致。

参考文献：
Yanpeng Xu, Liqi Xie, Erhui Zhang, Wenyuan Gao, Linlin Wang, Yang Cao, Michael Hongwei Xie, Weidong Jiang & Scott Liu (2019) Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®, mAbs, DOI: 10.1080/19420862.2019.1578147